Profit before payment of interest, taxes and amortization: novartis.com (NVS)

Graphic logo of novartis.com (NVS)

The EBITDA metric demonstrates actual cash flow, where the value 22082.91 determines the parameter status. The supply stability of Novartis AG (NVS) is based on an extensive network of European plants. The Swiss brand authority guarantees physician trust, while the strategic focus on radionuclide therapy and new molecules creates powerful growth potential, offsetting the risks of expiring legacy patents.

Novartis AG (NVS) - Operating profit EBITDA from 11/23/2025 to 11/11/2026

Novartis (NVS) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Novartis Pharma|NVS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Novartis|NVS - Enterprise Value
- business book valuation details:
Equity per Share Novartis|NVS - Book Capitalization|Market Capitalization to Book Value novartis.com|NVS - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Novartis AG|NVS - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Novartis Corporation|NVS - Company Debts|Debt to Book Value Ratio Novartis|NVS - Company Long-Term Debt|Short-Term Debt Novartis|Quick Liquidity novartis.com
- earnings and valuation multiples indicators:
NVS - Net Profit|Projected Future Earnings Novartis AG|NVS - Price to Earnings Ratio|Future Price to Earnings Multiple novartis.com|NVS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Novartis|NVS - Operating profit EBITDA|Net earnings per share for the last four quarters Novartis|NVS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months novartis.com|NVS - Net earnings per share growth this year|Expected earnings per share trend next year Novartis AG
Analysis of all company metrics:Novartis Pharma - NVS
Flagship merchandise of Novartis

Absolute operating profit measures the actual cash flow from core operations before taxes and interest expenses. The EBITDA trend visualizes the business's actual resilience to market shocks. This metric allows for an assessment of cash generation efficiency without the influence of capital structure. For Novartis AG (NVS), this indicator confirms the success of its transformation into an innovative developer. Profit growth here depends directly on the margins of key drugs and the protection of patents against generics.

Competitors of Novartis AG (NVS)

Eli Lilly and Co. (LLY) - Profit before interest, taxes and amortization|ABBV - Profit before payment of interest, taxes and amortization|AZN: Profit before payment of interest, taxes and amortization|MRK: Operating profit EBITDA|Operating profit before amortization NVO|AMGN (Amgen Corporation) - Operating profit EBITDA|Pfizer Corp (PFE) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sanofi (SNY)|bms.com - Operating profit before amortization|Operating profit EBITDA GSK (GlaxoSmithKline)|Operating profit before depreciation charges Takeda Pharmaceutical Company|TEVA - Profit before payment of interest, taxes and amortization|RDY (Dr. Reddy's Labs) - Operating profit before amortization|Viatris Inc. (VTRS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization roivant.com (ROIV)|Operating profit before deduction of amortization ZLAB|Profit before payment of interest, taxes and amortization BHC|Operating profit EBITDA COSM